156 related articles for article (PubMed ID: 32388115)
1. Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents.
Han J; Fu J; Yang Q; Zhou F; Chen X; Li C; Yin J
Eur J Med Chem; 2020 Jul; 198():112389. PubMed ID: 32388115
[TBL] [Abstract][Full Text] [Related]
2. Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents.
Han J; Huang Y; Chen X; Zhou F; Fei Y; Fu J
Eur J Med Chem; 2018 Sep; 157():177-187. PubMed ID: 30096651
[TBL] [Abstract][Full Text] [Related]
3. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
[TBL] [Abstract][Full Text] [Related]
4. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
[TBL] [Abstract][Full Text] [Related]
5. The chronic administration of two novel long-acting
Han J; Meng T; Chen X; Han Y; Fu J; Zhou F; Fei Y; Li C
FASEB J; 2019 Jun; 33(6):7113-7125. PubMed ID: 30860869
[TBL] [Abstract][Full Text] [Related]
6. Xenopus GLP-1-inspired discovery of novel GLP-1 receptor agonists as long-acting hypoglycemic and insulinotropic agents with significant therapeutic potential.
Han J; Chen X; Wang Y; Fei Y; Zhou F; Zhang Y; Liu L; Si P; Fu J
Biochem Pharmacol; 2017 Oct; 142():155-167. PubMed ID: 28668697
[TBL] [Abstract][Full Text] [Related]
7. Lipidation and conformational constraining for prolonging the effects of peptides: Xenopus glucagon-like peptide 1 analogues with potent and long-acting hypoglycemic activity.
Han J; Huang Y; Chen X; Zhou F; Fei Y; Fu J
Eur J Pharm Sci; 2018 Oct; 123():111-123. PubMed ID: 30031858
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of PEGylated Xenopus glucagon-like peptide-1 derivatives as long-acting hypoglycemic agents.
Han J; Wang Y; Meng Q; Li G; Huang F; Wu S; Fei Y; Zhou F; Fu J
Eur J Med Chem; 2017 May; 132():81-89. PubMed ID: 28342399
[TBL] [Abstract][Full Text] [Related]
9. Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-Like Peptide-1 Conjugates.
Han J; Zhou F; Fei Y; Chen X; Fu J; Qian H
Bioconjug Chem; 2018 Feb; 29(2):390-402. PubMed ID: 29239601
[TBL] [Abstract][Full Text] [Related]
10. A GLP-1/glucagon (GCG)/CCK
Zhao S; Yan Z; Du Y; Li Z; Tang C; Jing L; Sun L; Yang Q; Tang X; Yuan Y; Han J; Jiang N
Br J Pharmacol; 2022 Sep; 179(17):4360-4377. PubMed ID: 35484823
[TBL] [Abstract][Full Text] [Related]
11. Stapled and
Chen X; Fu J; Zhou F; Yang Q; Wang J; Feng H; Jiang W; Jin L; Tang X; Jiang N; Yin J; Han J
J Med Chem; 2020 Nov; 63(21):12595-12613. PubMed ID: 33125843
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule albumin ligand modification to enhance the anti-diabetic ability of GLP-1 derivatives.
Sun X; Zhang Z; Liu M; Zhang P; Nie L; Liu Y; Chen Y; Xu F; Liu Z; Zeng Y
Biomed Pharmacother; 2022 Apr; 148():112722. PubMed ID: 35202915
[TBL] [Abstract][Full Text] [Related]
13. Xenopus-derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities.
Han J; Fei Y; Zhou F; Chen X; Zhang Y; Liu L; Fu J
Br J Pharmacol; 2018 Feb; 175(3):544-557. PubMed ID: 29171021
[TBL] [Abstract][Full Text] [Related]
14. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent.
Liu C; Li C; Cai X; Zou Y; Mo J; Chen B; Cai Y; Han T; Huang W; Qian H; Zhang W
Bioorg Chem; 2021 Jan; 106():104492. PubMed ID: 33268008
[TBL] [Abstract][Full Text] [Related]
16. Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity.
Han J; Huang X; Sun L; Li Z; Qian H; Huang W
Biochem Pharmacol; 2013 Jul; 86(2):297-308. PubMed ID: 23707756
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.
Han J; Sun L; Chu Y; Li Z; Huang D; Zhu X; Qian H; Huang W
J Med Chem; 2013 Dec; 56(24):9955-68. PubMed ID: 24308627
[TBL] [Abstract][Full Text] [Related]
18. Novel mono-PEGylated dimeric GLP-1 conjugate with enhanced receptor activation and prolonged anti-diabetes efficacies.
Li P; Zhang J; Jia Y; Zhang Y
Life Sci; 2020 Aug; 254():117752. PubMed ID: 32387412
[TBL] [Abstract][Full Text] [Related]
19. S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors.
Huang P; Meng L; Tan J; Gu X; Huang M; Huang F; Ma R; Wang J
Life Sci; 2021 Apr; 270():119136. PubMed ID: 33508289
[TBL] [Abstract][Full Text] [Related]
20. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
